ModeX starts dosing in MDX2003 trial for B-cell lymphoma

OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Pharmabiz

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway

Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.

B cells that fight infections may also boost muscle performance during exercise

B cells are white blood cells that form a core part of the body's adaptive immune system, enabling it to recognize specific ...